Hypoxia in DU-145 Prostate Cancer Xenografts after Estramustine Phosphate and Radiotherapy

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|3|1|19-24

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.3, Iss.1, 2010-01, pp. : 19-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy

By  

Current Radiopharmaceuticals, Vol. 3, Iss. 4, 2010-10 ,pp. : 297-303

Bentham Science Publishers

Access to resources Recommend Favorite

Estramustine phosphate sodium-based regimen in prostate cancer

By  

Inpharma, Vol. 1, Iss. 1337, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Estramustine Phosphate

By Bergenheim A.T.  

Clinical Pharmacokinetics, Vol. 34, Iss. 2, 1998-02 ,pp. : 163-172

Adis International

Access to resources Recommend Favorite

Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells

By  

Current Cancer Drug Targets, Vol. 10, Iss. 3, 2010-01 ,pp. : 307-318

Bentham Science Publishers

Access to resources Recommend Favorite

CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells

By  

Current Pharmaceutical Design, Vol. 20, Iss. 2, 2014-01 ,pp. : 180-188

Bentham Science Publishers

Access to resources Recommend Favorite